GT Apeiron Therapeutics

Targeting the cancer cell cycle with next generation CDK inhibitors

Category
Oncology
Location
Shanghai, China and San Francisco, CA
Website
Visit website

About the company

Clinical stage small molecule biotech company developing biomarker-driven cancer therapeutics. Lead program is a potential best-in-class MTA-cooperative PRMT5 inhibitor currently in Phase 1 clinical study. Company is also developing a potential best-in-class KIF18A inhibitor with differentiated profile